Tobrex eye drops are a powerful broad-spectrum antibiotic. The drug is part of the aminoglycoside group.
Tobrex eye drops have an antibacterial effect due to the suppression of the polypeptide complex and synthesis in microbial ribosomes.
The medicine is used in ophthalmology to treat external infections of the eyes and their appendages.
The active substance of the drug is Tobramycin.
Tobrex eye drops are contraindicated in case of hypersensitivity (not excluding other aminoglycosides), myasthenia gravis, chronic kidney failure, parkinsonism, dehydration, dysfunction in the eighth pair of cranial nerves, in old age and during pregnancy.
Using the drug may cause adverse reactions. The most common are lesions of the auditory and vestibular branches of the eighth pair of nerves with complete (partial) deafness on both sides, dizziness, tinnitus, vertigo, drowsiness, cramps, orientation disorders, muscle fasciculations, cylinduria, tubular renal impairment, increased nitrogen and urea creatinine. In addition, anemia, leukocytosis, nausea, thrombocytopenia, eosinophilia, diarrhea, fever, anaphylaxis, pruritus, hyponatomy, rash can be noted. Conjunctival use can provoke allergic manifestations in the form of a tumor on the eyelids, itching.
Tobrex eye drops are able to increase the nephro- and neurotoxicity of other medicines. The risk of adverse reactions increases with the combined use of loop diuretics (ethacrylic acid, furosemide). The likelihood of a neuromuscular blockade increases with the use of tububurarin, decametonium, and succinicylcholine.
An overdose of the drug is noted in the form of impaired renal function, auditory and vestibular disorders, paralysis of the respiratory muscles, neuromuscular blockade.
Treatment consists in ensuring adequate oxygenation and ventilation, hydration while controlling fluid balance.
Tobrex (eye drops) are applied conjunctively one drop five times a day. In acute infections, administration is allowed every half hour or an hour.
For long-term use, Tobrex drops are not recommended.
During treatment, patients should be provided with strict medical supervision due to the potential likelihood of developing nephrotoxic and neurotoxic effects. Regular audiometric tests are recommended. It should be borne in mind that complete or partial hearing loss in a number of patients may develop after completion of the therapeutic course.
In the case of an increase in volume in the distribution of the drug (burns, peritonitis, infection in the retroperitoneal space), optimal concentration is achieved by increasing the dose. In young patients with high cardiac output and glomerular filtration rate to increase the effect of the introduction produce more often. For patients with impaired renal function and elderly patients, the dosage should be reduced, and the intervals between instillation should be increased. Regular determination of calcium, urea nitrogen, plasma magnesium, sodium, creatinine, urinary sediment, urine density (relative), protein is recommended.
Prolonged local use of the drug Tobrex can provoke superinfection, including fungal infection.
Nursing patients during the course of therapy should stop breastfeeding.
When using contact lenses before administration of the drug, they must be removed. You can install them back no less than fifteen minutes after instillation.